Strand Therapeutics

Where synthetic biology meets mRNA therapeutics

[Strand Therapeutics @StrandTx]

@Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

[Strand Therapeutics @StrandTx]

"We are standing right now on the precipice of a revolution in genetic medicine."

Strand CEO @DrSynbio on @tferriss' podcast. Full episode: https://t.co/oP8Bh6QSSG

[Tim Ferriss @tferriss]

NEW podcast episode is up!

"Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)"

This episode is an experiment!

I'm trying out a new format: half interview, half live jam session. I've started a new series, working title "Tim's Founder Kitchen," built around actual brainstorming sessions with founders willing to share the audio.

This first instalment is with Jake Becraft of Strand Therapeutics. @DrSynbio is the CEO and co-founder of @StrandTx, a clinical-stage biotechnology company with a pipeline of breakthrough mRNA therapeutics for cancers and autoimmune diseases.

Let me know by replying here what you think of this experiment and how I can make the series better.

Please enjoy!

[Strand Therapeutics @StrandTx]

@Nasdaq Read more: https://t.co/wicPTrJhDM

[Strand Therapeutics @StrandTx]

Hard to miss Kunal Bhatia on the @Nasdaq tower in Times Square, featuring his appointment as Chief Financial Officer.

In Kunal’s words, “I joined Strand because I believe we are one of the most innovative biotech companies today; importantly, we are prosecuting a big vision with rigor and intense focus.”

Glad to have him helping lead this next chapter

[Strand Therapeutics @StrandTx]

What if a medicine could decide when and where to activate inside your body?

Strand co-founder and CEO @DrSynbio joined the @ProgressPotent1 podcast with @irat1onal to discuss programmable mRNA therapeutics, Strand’s origins at MIT, and what early clinical results mean for the future of genetic medicine.

Listen here: https://t.co/TURP1BBzbF

[Strand Therapeutics @StrandTx]

Thursday morning, our Chief Medical Officer @jasonlukemd joins leaders from @IN8bio, @MedicalCollege, and @advarra for a @FiercePharma webinar on translating cutting-edge oncology science into operationally executable trials.

The conversation will cover adaptive trial design, patient access, and what it actually takes to run next-generation oncology studies at scale.

🔬Don't miss it! Register at the link below.

https://t.co/r0WAyd3PrG

[Strand Therapeutics @StrandTx]

mRNA therapeutics are a powerful modality. It's also one where you can’t take shortcuts if you want to succeed, and circular RNA (circRNA) is no different.

In a new interview with @PharmaScrip’s @awmcconaghie, our co-founder, President, and Head of R&D @tasuku_kitada breaks down what it takes to build an in vivo CAR-T platform that can deliver in the clinic: optimized circRNA architecture, targeted lipid nanoparticle (LNP) delivery, and programmable safety controls built directly into the construct.

With major pharma bets pouring into the space, Tasuku makes the case that the companies that win will be the ones that did the engineering work before rushing to the clinic.

Read more: https://t.co/K7XIxVkN3D

[Strand Therapeutics @StrandTx]

Circular RNA is emerging as one of the most exciting frontiers in gene and cell therapy. At Strand, we've been building on it for years.

BioWorld's @MarJungle covered the latest advances at #ASGCT2026, including a conversation with our co-founder, President, and Head of R&D @tasuku_kitada. They discuss how Strand is using circRNA to power STX-005, our in vivo CAR-T program designed to be a redosable, off-the-shelf approach to cell therapy.

Read more: https://t.co/dLV7Lneylf

[Strand Therapeutics @StrandTx]

Strand stays committed to fostering the next generation of scientists. Shoutout to Strands Eloise, Gautam and Daniel for participating as judges for the MSEF Middle School Science Fair this past weekend!

[Strand Therapeutics @StrandTx]

Programmable RNA is coming for in vivo CAR-T.

Tomorrow at #ASGCT2026, our Principal Scientist Ashlesha Odak, Ph.D. is presenting preclinical NHP data showing how programmable circRNA, combined with a targeted LNP approach, can generate functional CAR-T cells in vivo with integrated safety controls.

No cell extraction, no manufacturing facility. This is pioneering what's possible in programmable genetic medicine.

Watch the presentation to find out for yourself:
📢 LNPs for in vivo CAR-T applications
📅 Tuesday, May 12, at 9:00-9:15 am ET
📍 MCEC Room 210 ABC (Level 2)

Presentation abstract can be found here: https://t.co/MCqdihWRNt

[Strand Therapeutics @StrandTx]

Our CEO @DrSynbio sat down with @FierceBiotech’s @Angus_Fierce to talk about the regulatory and manufacturing barriers slowing first-in-human clinical trials in the U.S., and what a more efficient pathway to first-in-human trials could mean for American patients.

Read the conversation here: https://t.co/ZYwivDCuMB

[Strand Therapeutics @StrandTx]

You can find the full agenda here: https://t.co/MjZfJRmcwA

[Strand Therapeutics @StrandTx]

How are advances in sequence design, delivery, and manufacturing closing the gap between computational insight and real-world medicines?

Join @tasuku_kitada, co-founder, President, and Head of R&D at Strand Therapeutics, at @SynBioBeta on Wednesday, May 6, for a panel on one of the most important questions in programmable medicine.

We hope to see you there!

[Strand Therapeutics @StrandTx]

Strand Therapeutics is heading to the @MilkenInstitute Global Conference 2026 in Los Angeles. On May 4 at 10 a.m. PT, our CEO and co-founder, @DrSynbio, will join an invitation-only panel on sustaining American leadership in biomedical innovation.

He’ll be joined by @SecAzar, 24th U.S. Secretary of Health and Human Services; @mmrozenman, CFO and CBO of @insitro; and @rtnarch, co-founder and managing director of ARCH Venture Partners. The session will be moderated by @SungHeeTweets, managing director of FasterCures at Milken Institute Health.

Looking forward to continuing the conversation at #MIGlobal.

https://t.co/4E98iq0tmD

[Strand Therapeutics @StrandTx]

We're excited to welcome Kunal Bhatia to Strand as Chief Financial Officer.

Kunal brings 15 years of investment banking experience advising biopharmaceutical companies on financing and business development, most recently as interim CFO and CBO to a portfolio of life sciences companies.

His appointment comes as Strand advances a growing pipeline – STX-001 clinical data, STX-003 heading to the clinic in mid-2026, and our in vivo CAR-T program – and builds on a $153M Series B.

As we enter this next chapter, Kunal's expertise in capital formation and strategic partnerships positions Strand to keep advancing our mission of integrating programmable genetic medicines into the core of modern therapeutics.

Read more: https://t.co/HCxxAVasL2

[Strand Therapeutics @StrandTx]

Generating CAR-T cells inside the body, without removing and reengineering a patient's cells, has long been one of cell therapy's most persistent unsolved challenges. We're presenting data at #ASGCT2026 with data that shows how programmable mRNA can deliver on it.

Ashlesha Odak, PhD will go over preclinical findings from the circRNA-LNP platform showing near-complete B cell depletion in non-human primates following IV dosing, with programmable safety controls built in.

Presentation details below. Full abstract here: https://t.co/9621aUBPK6

Abstract Title: Programmable circRNA-tLNP platform enables efficient in vivo CAR-T cell programming and robust activity in a NHP model
Session Type: Oral
Session Name: LNPs for in vivo CAR-T applications
Date and Time: Tuesday, May 12, 2026, at 9:00-9:15 am ET
Location: MCEC Room 210 ABC (Level 2)

[Strand Therapeutics @StrandTx]

@DrSynbio @EY_US Read more here: https://t.co/iXJn2w7upt

[Strand Therapeutics @StrandTx]

Congratulations to our co-founder and CEO @DrSynbio, named a finalist for the @EY_US Entrepreneur Of The Year 2026 New England Award.

Jake built Strand on a single conviction: mRNA could be programmed to know the difference between healthy and diseased cells. That idea is what this recognition reflects, and what we believe the future of genetic medicine will be built on.

Congrats, Jake!

[Strand Therapeutics @StrandTx]

Happy belated Earth Day from Strand Therapeutics! 🌎 Strands celebrated by taking public transit to work, swapping disposable cups and bottles for reusable bottles, eating plant based, donating clothing, and cleaning up litter near our office!

[Strand Therapeutics @StrandTx]

@Annals_Oncology @jasonlukemd Read more: https://t.co/emTkh8BFCi

[Strand Therapeutics @StrandTx]

What does it take to make immunotherapy safer for every patient?

A new manuscript in @Annals_Oncology co-authored by our CMO @jasonlukemd takes on a piece of that puzzle: how Cytokine Release Syndrome (CRS) is graded and reported in trials.

The authors call for granular, symptom-driven reporting to cut diagnostic ambiguity and enable safety comparisons across global trials. As Strand advances our own therapies into solid tumors and beyond, building the right safety infrastructure as the field scales is essential.